Fagron
Fagron, a leading global player in the pharmaceutical industry, is headquartered in the Netherlands (NL) and operates extensively across Europe, North America, and Latin America. Founded in 1990, the company has established itself as a pioneer in customised medicines, focusing on compounding and innovative pharmaceutical solutions tailored to individual patient needs. Fagron's core offerings include a diverse range of pharmaceutical products and services, such as sterile and non-sterile compounding, as well as advanced drug delivery systems. What sets Fagron apart is its commitment to quality and innovation, ensuring that healthcare professionals have access to tailored therapies that enhance patient outcomes. With a strong market position and a reputation for excellence, Fagron continues to achieve significant milestones in the pharmaceutical sector, reinforcing its status as a trusted partner in personalised medicine.
DitchCarbon Score
How does Fagron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fagron's score of 59 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fagron's reported carbon emissions
In 2024, Fagron, headquartered in the Netherlands, reported total carbon emissions of approximately 293,227,000 kg CO2e. This figure includes 3,871,000 kg CO2e from Scope 1 emissions, 6,554,000 kg CO2e from Scope 2 (market-based), and a significant 282,802,000 kg CO2e from Scope 3 emissions. The company's emissions have shown a slight increase from 2023, where total emissions were about 273,399,000 kg CO2e. Fagron has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the baseline year. Additionally, the company plans to cut its absolute Scope 3 emissions by 25% within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Fagron's commitment to sustainable practices in the healthcare equipment and supplies sector. The company has also committed that by 2027, 60% of its suppliers, measured by emissions from purchased goods and services, will have established science-based targets. This initiative underscores Fagron's dedication to reducing its overall environmental impact and promoting sustainability throughout its supply chain.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 2,818,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 8,200,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 2,477,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fagron is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
